四川省学术技术带头人，四川省卫健委临床药学“首席专家”，四川省卫健委学术和技术带头人，国家卫健委药事质控专家委员会委员，国家卫健委医院管理研究所信息药学专家委员会副主任委员，中华医学会临床药学专委会常委，中国药学会医院药专委会委员，四川省医学会临床药学专委会主委等。

代表论著（仅列20篇）：

1. Zhang J, Huang Y, Li H, Xu P, Liu Q, Sun Y, Zhang Z, Wu T, Tang Q, Jia Q, Xia Y, Xu Y, Jing X, Li J, Mo L, Xie W, Qu A, He J^*, Li Y^*. B3galt5 functions as a PXR target gene and regulates obesity and insulin resistance by maintaining intestinal integrity. Nat Commun. 2024, 15(1):5919. (IF=14.7)

2. Zhang J, Zhang T, Zhang Z, Jia Q, Chen J, Li J, Song H, Li J, Xiong Y, Mo L, He J^*, Li Y^*. The Dual-Target Nanoparticles with ROS Sensitivity Inhibit the Hedgehog Signaling Pathway and Decrease Oxidative Stress in Activated Hepatic Stellate Cells to Alleviate Liver Fibrosis, Advanced Functional Materials, 2024, 2404658. (IF=18.5) 

3. Chen W, Zhu Y, Chen J, Jing X, Xiong Y, Zou L, Li J, Liu Q, Li Y, Huang Y, He J^*. Potentiating the Systemic Immunity by Bacteria-Delivered Sting Activation in a Tumor Microenvironment, Advanced Functional Materials, 2023, 33:2307001. (IF=18.5)

4. Li Y, Zhang T, Zhang J, Liu Q, Jia Q, Chen W, Tang Q, Xiong Y, Xia Y, Xu Y, Mo L, Huang Y, He J^*. Dually fibronectin/CD44-mediated nanoparticles targeted disrupt the Golgi apparatus and inhibit the hedgehog signaling in activated hepatic stellate cells to alleviate liver fibrosis. Biomaterials. 2023, 301: 122232. (IF=14.0)

5. Xia Y, Xu Y, Liu Q, Zhang J, Zhang Z, Jia Q, Tang Q, Jing X, Li J, Chen J, Xiong Y, Li Y^*, He J^*. Glutaredoxin 1 regulates cholesterol metabolism and gallstone formation by influencing protein S-glutathionylation. Metabolism. 2023,145:155610. (IF=10.8)

6. Li R, Zhang J, Liu Q, Tang Q, Jia Q, Xiong Y, He J^*, Li Y^*. CREKA-modified liposomes target activated hepatic stellate cells to alleviate liver fibrosis by inhibiting collagen synthesis and angiogenesis. Acta Biomater. 2023,168:484-496. (IF=9.4)

7. Tang Q, Liu Q, Li J, Yan J, Jing X, Zhang J, Xia Y, Xu Y, Li Y, He J^*. MANF in POMC neurons promotes brown adipose tissue thermogenesis and protects against diet-induced obesity. Diabetes. 2022,71(11):2344-2359. (IF=6.2)

8. Tang Q, Li Y, He J^*. MANF: an emerging therapeutic target for metabolic diseases. Trends Endocrinol Metab. 2022,33(4):236-246 2022. (IF=11.4)

9. Xi Y, Li Y, Xu P, Li S, Liu Z, Tung HC, Cai X, Wang J, Huang H, Wang M, Xu M, Ren S, Li S, Zhang M, Lee YJ, Huang L, Yang D, He J^*, Huang Z^*, Xie W^*. The anti-fibrotic drug pirfenidone inhibits liver fibrosis by targeting the small oxidoreductase glutaredoxin-1. Sci Adv. 2021,7(36): eabg9241. (IF=11.7)

10. Wu T, Liu Q, Li Y, Li H, Chen L, Yang X, Tang Q, Pu S, Kuang J, Li R, Huang Y, Zhang J, Zhang Z, Zhou J, Huang C, Zhang G, Zhao Y, Zou M, Jiang W, Mo L^*, He J^*. Feeding-induced hepatokine, Manf, ameliorates diet-induced obesity by promoting adipose browning via p38 MAPK pathway. J Exp Med. 2021,218(6):e20201203. (IF=12.6)

11. Zhang J, Li Y, Liu Q, Huang Y, Li R, Wu T, Zhang Z, Zhou J, Huang H, Tang Q, Huang C, Zhao Y, Zhang G, Jiang W, Mo L, Zhang J, Xie W, He J^*. Sirt6 alleviated liver fibrosis by deacetylating conserved lysine 54 on Smad2 in hepatic stellate cells. Hepatology. 2021,73(3):1140-1157. (IF=12.9)

12. Zhang Z, Du Z, Liu Q, Wu T, Tang Q, Zhang J, Huang C, Huang Y, Li R, Li Y, Zhao Y, Zhang G, Zhou J, Huang H, Fang Z^*, He J^*. Glucagon-like peptide 1 analogue prevents cholesterol gallstone formation by modulating intestinal farnesoid X receptor activity. Metabolism. 2021,118:154728. (IF=10.8)

13. Yang X, Liu Q, Li Y, Ding Y, Zhao Y, Tang Q, Wu T, Chen L, Pu S, Cheng S, Zhang J, Zhang Z, Huang Y, Li R, Zhao Y, Zou M, Shi X, Jiang W, Wang R^*, He J^*. SGLT2 inhibition by canagliflozin ameliorates diet-induced obesity by promoting intra-adipose sympathetic innervation. Br J Pharmacol. 2021,178(8):1756-1771. (IF=6.8)

14. Huang C, Liu Q, Tang Q, Jing X, Wu T, Zhang J, Zhang G, Zhou J, Zhang Z, Zhao Y, Huang H, Xia Y, Yan J, Xiao J^*, Li Y^*, He J^*. Hepatocyte-specific deletion of Nlrp6 in mice exacerbates the development of non-alcoholic steatohepatitis. Free Radic Biol Med. 2021,169:110-121. (IF=7.1)

15. Tang Q, Gao Y, Liu Q, Yang X, Wu T, Huang C, Huang Y, Zhang J, Zhang Z, Li R, Pu S, Zhang G, Zhao Y, Zhou J, Huang H, Li Y, Jiang W, Chang Y^*, He J^*. Sirt6 in pro-opiomelanocortin neurons controls energy metabolism by modulating leptin signaling. Mol Metab. 2020,37:100994. (IF=7.0)

16. Li R, Li Y, Zhang J, Liu Q, Wu T, Zhou J, Huang H, Tang Q, Huang C, Huang Y, Zhang Z, Zhang G, Zhao Y, Ma L, Feng Y, Mo L, Han M^*, He J^*. Targeted delivery of celastrol to renal interstitial myofibroblasts using fibronectin-binding liposomes attenuates renal fibrosis and reduces systemic toxicity. J Control Release. 2020,320:32-44. (IF=10.5)

17. Mao Z, Lin H, Su W, Li J, Zhou M, Li Z, Zhou B, Yang Q, Zhou M, Pan K, He J^*, Zhang W^*. Deficiency of ZnT8 promotes adiposity and metabolic dysfunction by increasing peripheral serotonin production. Diabetes. 2019,68(6):1197-1209. (IF=6.2)

18. Li Y, Pu S, Liu Q, Li R, Zhang J, Wu T, Chen L, Li H, Yang X, Zou M, Xiao J, Xie W^*, He J^*. An integrin-based nanoparticle that targets activated hepatic stellate cells and alleviates liver fibrosis. J Control Release. 2019,303:77-90. (IF=10.5)

19. Chen L, Liu Q, Tang Q, Kuang J, Li H, Pu S, Wu T, Yang X, Li R, Zhang J, Zhang Z, Huang Y, Li Y, Zou M, Jiang W, Li T, Gong M, Zhang L, Wang H, Qu A, Xie W^*, He J^*. Hepatocyte-specific Sirt6 deficiency impairs ketogenesis. J Biol Chem. 2019,294(5):1579-1589. (IF=4.0) 

20. Kuang J, Zhang Y, Liu Q, Shen J, Pu S, Cheng S, Chen L, Li H, Wu T, Li R, Li Y, Zou M, Zhang Z, Jiang W, Xu G, Qu A, Xie W, He J^*. Fat-specific sirt6 ablation sensitizes mice to high-fat diet-induced obesity and insulin resistance by inhibiting lipolysis. Diabetes. 2017,66(5):1159-1171.